Literature DB >> 6138995

Chronic non-cytopathic infection of human continuous cell lines with mumps virus.

O G Andzhaparidze, N N Bogomolova, I D Drynov.   

Abstract

Chronic infection with a vaccine strain of mumps virus (MV) was produced and studied in human cell cultures L-41 and HEp-2. The establishment and course of the infection was not accompanied by cytopathic changes. Among probable protective factors (mechanisms) interferon (IFN) was detected in L-41 culture and defective interfering particles in either cell culture. Their role in the establishment and maintenance of chronic infection was not confirmed, however.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138995

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  5 in total

Review 1.  A Virus Is a Community: Diversity within Negative-Sense RNA Virus Populations.

Authors:  Lavinia J González Aparicio; Carolina B López; Sébastien A Felt
Journal:  Microbiol Mol Biol Rev       Date:  2022-06-23       Impact factor: 13.044

2.  A universal mammalian vaccine cell line substrate.

Authors:  Jackelyn Murray; Kyle V Todd; Abhijeet Bakre; Nichole Orr-Burks; Les Jones; Weilin Wu; Ralph A Tripp
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

Review 3.  Defective viral genomes are key drivers of the virus-host interaction.

Authors:  Marco Vignuzzi; Carolina B López
Journal:  Nat Microbiol       Date:  2019-06-03       Impact factor: 17.745

4.  Generation and functional analysis of defective viral genomes during SARS-CoV-2 infection.

Authors:  Terry Zhou; Nora J Gilliam; Sizhen Li; Simone Spaudau; Raven M Osborn; Christopher S Anderson; Thomas J Mariani; Juilee Thakar; Stephen Dewhurst; David H Mathews; Liang Huang; Yan Sun
Journal:  bioRxiv       Date:  2022-09-23

Review 5.  Defective (interfering) viral genomes re-explored: impact on antiviral immunity and virus persistence.

Authors:  Tomaz B Manzoni; Carolina B López
Journal:  Future Virol       Date:  2018-06-12       Impact factor: 1.831

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.